Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Meningeal Carcinomatosis 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Pemetrexed 5Topotecan 3Dexamethasone 3Bevacizumab 3osimertinib 2Vitamin B 12 2Trastuzumab 2Spinal Puncture 2Radiotherapy 2Methotrexate 2Folic Acid 2Cytarabine 2Busulfan 2trioctyl phosphine oxide 1trastuzumab deruxtecan 1tipifarnib 1merphos 1mafosfamide 1immunotoxin LMB-7 1epothilone B 1avelumab 1aflutinib 1XL647 1Transplantation, Autologous 1Temozolomide 1Rituximab 1Referral and Consultation 1Radiotherapy, Intensity-Modulated 1Nivolumab 1Mental Status and Dementia Tests 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Meningeal Carcinomatosis × aflutinib × Clear all
NCT06812871 2026-04-02

High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

Sun Yat-sen University

Phase 2 Completed
46 enrolled
CNS

Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡